FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
World game at war: why some European nations have threatened a World Cup boycott 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2018 -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the Company is scheduled to present new data on its allogeneic CRISPR-based CAR-T programs at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 16, 2018 in Chicago, IL.
Presentation: Allogeneic chimeric antigen receptor T cells targeting B cell maturation antigen
Session: Adoptive Cell Therapy 1
Time and Date: 8:00 AM – 12:00 PM CDT, Monday, April 16, 2018
Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 1540
Presentation: Allogeneic CRISPR engineered anti CD70 CAR T cells demonstrate potent preclinical activity against both solid and hematological cancer cells
Session: Adoptive Cell Therapy 2
Time and Date: 1:00 PM - 5:00 PM CDT, Monday, April 16, 2018
Location: McCormick Place South (Level 3), Exhibit Hall A, Section 24, Poster 2551
Following presentation at the meeting, the posters will be available on CRISPR Therapeutics’ website at http://www.crisprtx.com.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The Company has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.
CONTACTS
CRISPR Therapeutics
Investors:
Chris Erdman
617-307-7227
[email protected]
or
Chris Brinzey
Westwicke Partners
339-970-2843
[email protected]
Media:
Jennifer Paganelli
WCG for CRISPR
347-658-8290
[email protected]
